Silodosin
Silodosin
Silodosin (Flomax) is a selective alpha-1A adrenergic receptor antagonist designed to relax smooth muscle in the prostate, bladder neck, and urethra, helping improve urinary flow and reduce lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Its high affinity for the alpha-1A subtype supports targeted uroselective action, making it a focused option for urinary comfort and prostate-related symptom management.
Couldn't load pickup availability
Share

What is Silodosin?
Silodosin is a highly uroselective alpha-1 adrenergic receptor antagonist primarily developed for the management of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). It works by selectively blocking alpha-1A adrenergic receptors located in the prostate, bladder neck and prostatic urethra, allowing smooth muscle in these structures to relax. This reduces resistance to urinary flow and helps alleviate common urinary symptoms associated with prostate enlargement. What makes Silodosin particularly interesting is its strong preference for alpha-1A receptors over other alpha-1 receptor subtypes, potentially limiting some of the cardiovascular effects associated with less selective alpha-blockers.
What makes Silodosin unique?
Clinical research has demonstrated that Silodosin can produce relatively rapid improvements in urinary symptoms, including weak stream, hesitancy, incomplete bladder emptying, urinary frequency and nocturia. In two large randomized, placebo-controlled Phase III trials, Silodosin significantly improved International Prostate Symptom Scores (IPSS) and maximum urinary flow rates, with measurable improvements observed as early as the first day of treatment. Its high receptor selectivity makes it an important compound in urological research, particularly concerning prostate-related urinary obstruction and lower urinary tract function.
Key research benefits:
- Prostate Smooth-Muscle Relaxation – Selectively blocks alpha-1A adrenergic receptors, reducing smooth-muscle tension in the prostate and bladder neck.
- Improved Urinary Flow – Clinical trials demonstrate improvements in maximum urinary flow rate (Qmax).
- BPH Symptom Relief – Clinically investigated for reducing lower urinary tract symptoms associated with benign prostatic hyperplasia.
- Reduced Urinary Hesitancy – Helps reduce resistance at the bladder outlet, facilitating easier initiation of urination.
- Reduced Nocturia – Investigated for improving nighttime urinary frequency associated with BPH.
- Improved Bladder Emptying – Reduces functional obstruction at the bladder outlet, potentially improving urinary emptying.
- Reduced Urinary Frequency and Urgency – Clinical studies have demonstrated improvements in both storage and voiding symptoms.
- Rapid Onset of Action – Studies have demonstrated measurable improvements in urinary flow within hours of initial administration.
- High Alpha-1A Selectivity – Demonstrates substantially greater affinity for alpha-1A receptors than alpha-1B and alpha-1D subtypes.
- Uroselective Activity – Its receptor selectivity is associated with a relatively low incidence of orthostatic hypotension compared with some less selective alpha-blockers.
- Lower Urinary Tract Research – Provides an established pharmacological approach for investigating alpha-adrenergic regulation of bladder outlet resistance.
- Bladder Function Research – Investigated for effects on bladder outlet obstruction and associated detrusor overactivity.
- Evidence-Based Pharmacology – Supported by multiple randomized, double-blind, placebo-controlled clinical trials in men with BPH.
What is Silodosin?
Silodosin is a highly uroselective alpha-1 adrenergic receptor antagonist primarily developed for the management of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). It works by selectively blocking alpha-1A adrenergic receptors located in the prostate, bladder neck and prostatic urethra, allowing smooth muscle in these structures to relax. This reduces resistance to urinary flow and helps alleviate common urinary symptoms associated with prostate enlargement. What makes Silodosin particularly interesting is its strong preference for alpha-1A receptors over other alpha-1 receptor subtypes, potentially limiting some of the cardiovascular effects associated with less selective alpha-blockers.
What makes Silodosin unique?
Clinical research has demonstrated that Silodosin can produce relatively rapid improvements in urinary symptoms, including weak stream, hesitancy, incomplete bladder emptying, urinary frequency and nocturia. In two large randomized, placebo-controlled Phase III trials, Silodosin significantly improved International Prostate Symptom Scores (IPSS) and maximum urinary flow rates, with measurable improvements observed as early as the first day of treatment. Its high receptor selectivity makes it an important compound in urological research, particularly concerning prostate-related urinary obstruction and lower urinary tract function.
Key research benefits:
- Prostate Smooth-Muscle Relaxation – Selectively blocks alpha-1A adrenergic receptors, reducing smooth-muscle tension in the prostate and bladder neck.
- Improved Urinary Flow – Clinical trials demonstrate improvements in maximum urinary flow rate (Qmax).
- BPH Symptom Relief – Clinically investigated for reducing lower urinary tract symptoms associated with benign prostatic hyperplasia.
- Reduced Urinary Hesitancy – Helps reduce resistance at the bladder outlet, facilitating easier initiation of urination.
- Reduced Nocturia – Investigated for improving nighttime urinary frequency associated with BPH.
- Improved Bladder Emptying – Reduces functional obstruction at the bladder outlet, potentially improving urinary emptying.
- Reduced Urinary Frequency and Urgency – Clinical studies have demonstrated improvements in both storage and voiding symptoms.
- Rapid Onset of Action – Studies have demonstrated measurable improvements in urinary flow within hours of initial administration.
- High Alpha-1A Selectivity – Demonstrates substantially greater affinity for alpha-1A receptors than alpha-1B and alpha-1D subtypes.
- Uroselective Activity – Its receptor selectivity is associated with a relatively low incidence of orthostatic hypotension compared with some less selective alpha-blockers.
- Lower Urinary Tract Research – Provides an established pharmacological approach for investigating alpha-adrenergic regulation of bladder outlet resistance.
- Bladder Function Research – Investigated for effects on bladder outlet obstruction and associated detrusor overactivity.
- Evidence-Based Pharmacology – Supported by multiple randomized, double-blind, placebo-controlled clinical trials in men with BPH.
Capsules
Composition: Each capsule contains 4mg Silodosin. Other ingredients - gelatin capsule & micro-crystalline cellulose.
Directions: Take 1 capsule (4mg), once per day with water.
Storage: Store at room temperature, tightly sealed, away from heat, light and moisture.
Capsules
Composition: Each capsule contains 4mg Silodosin. Other ingredients - gelatin capsule & micro-crystalline cellulose.
Directions: Take 1 capsule (4mg), once per day with water.
Storage: Store at room temperature, tightly sealed, away from heat, light and moisture.
- CAS: 160970-54-7
- Molar Mass: 495.53 g/mol
- Chemical Formula: C25H32F3N3O4
- Synonyms: Flomax, Rapaflo, Urief, Silodyx, Silodal
- CAS: 160970-54-7
- Molar Mass: 495.53 g/mol
- Chemical Formula: C25H32F3N3O4
- Synonyms: Flomax, Rapaflo, Urief, Silodyx, Silodal
At the core of our mission is an unwavering commitment to your health and trust: we employ a rigorous, multi-phase quality control system - backed by accredited certifications and total transparency - to ensure every product we stock is pure, safe, and consistently meets the highest industry standards. From material sourcing through final batch testing, our processes are continually refined to guarantee potency and prevent cross-contamination.
At the core of our mission is an unwavering commitment to your health and trust: we employ a rigorous, multi-phase quality control system - backed by accredited certifications and total transparency - to ensure every product we stock is pure, safe, and consistently meets the highest industry standards. From material sourcing through final batch testing, our processes are continually refined to guarantee potency and prevent cross-contamination.